Company news

Dyne Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 2, 2022

Dyne Therapeutics to Present at Investor Conferences in November

November 1, 2022

Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

October 30, 2022

Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress

October 10, 2022

Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 26, 2022

Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event

September 11, 2022

Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

September 5, 2022

Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

September 5, 2022

Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development

August 28, 2022

Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

August 9, 2022

Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 3, 2022

Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

July 11, 2022

Dyne Therapeutics Announces FDA Clearance of IND Application for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

July 4, 2022

Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown

May 15, 2022

Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

May 1, 2022

Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

March 9, 2022

Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors

March 2, 2022

Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy

January 17, 2022

Dyne Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 4, 2022

Dyne Therapeutics Announces Submission of IND Application to Initiate Clinical Trial of DYNE-251 for Duchenne Muscular Dystrophy

December 1, 2021

Dyne Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

November 3, 2021

Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day

October 12, 2021

Dyne Therapeutics Presents New In Vivo Data for its Duchenne Muscular Dystrophy Program During Muscle Study Group Annual Scientific Meeting Demonstrating Robust and Durable Exon Skipping and Dystrophin Expression

September 30, 2021

Dyne Therapeutics to Host Virtual Research and Development Day on Wednesday, October 13, 2021

September 27, 2021

Dyne Therapeutics to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference

September 26, 2021

Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress

September 19, 2021

Dyne Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

August 4, 2021

Dyne Therapeutics Presents Preclinical Data from its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

June 24, 2021

Dyne Therapeutics Announces Chief Scientific Officer Transition

June 1, 2021

Dyne Therapeutics to Present at Jefferies Virtual Healthcare Conference

May 25, 2021

Dyne Therapeutics Presents New Preclinical Data from its Myotonic Dystrophy Type 1 Program During American Society of Gene & Cell Therapy Annual Meeting Demonstrating Sustained Knockdown of Toxic Human Nuclear DMPK RNA

May 13, 2021

Dyne Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

May 5, 2021

New Preclinical Data from Dyne Therapeutics’ Myotonic Dystrophy Type 1 Program to be Featured in Presentations During Upcoming American Society of Gene & Cell Therapy Annual Meeting

April 26, 2021

Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights

March 3, 2021

Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer

March 3, 2021

Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs

February 7, 2021

Dyne Therapeutics Announces Pricing of $168 Million Public Offering

January 19, 2021

Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study

January 9, 2021

Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights

November 4, 2020

Dyne Therapeutics Announces Closing of Initial Public Offering

September 20, 2020

Dyne Therapeutics Announces Pricing of Initial Public Offering

September 15, 2020

← Newer news releases

Decks

The 5 newest of 15 decks. Every deck is listed under its year.